Navigation

Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy [ID414]

Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma

Status: History
Expected date of issue: February 2014
Referral date: November 2010
Process: STA
Topic area:
  • Cancer
 

NICE project team

Technical Lead: Linda Landells and Carl Prescott
Communications manager: Alice Law
Project manager:

Lori Farrar

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 28 November 2012
1st appraisal committee meeting: 13 March 2013
2nd appraisal committee meeting 15 May 2013
4th appraisal committee meeting: 13 November 2013
Top


 

Consultees and commentators

 

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Cell Therapeutics (pixantrone)

Patient/carer groups

  • Leukaemia CARE
  • Lymphoma Association
  • South Asian Health Foundation

Professional groups

  • British Society for Haematology
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Greater Manchester (PCT Cluster)
  • South Essex (PCT Cluster)
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland

Comparator manufacturers

  • Actavis UK (vinorelbine ditartrate, oxaliplatin, gemcitabine) (CA&U not returned, not participating)
  • Baxter Healthcare (mitoxantrone hydrochloride, ifosfamide) (CA&U not returned, not participating)
  • Bristol-Myer Squibb Pharmaceuticals (etoposide)
  • Lilly UK (gemcitabine)
  • Hospira UK (gemcitabine, vinorelbine ditartrate, oxaliplatin, mitoxantrone hydrochloride, etoposide) (CA&U not returned, not participating)
  • Medac UK (gemcitabine, vinorelbine ditartrate, oxaliplatin, etoposide) (CA&U not returned, not participating)
  • Mylan UK (oxaliplatin) (CA&U not returned, not participating)
  • Pfizer (mitoxantrone hydrochloride)
  • Pierre Fabre (vinorelbine ditartrate) (CA&U not returned, not participating)
  • Sanofi-aventis (oxaliplatin) (CA&U not returned, not participating)
  • Sun Pharmaceuticals UK (gemcitabine) (CA&U not returned, not participating)
  • Teva UK (oxaliplatin, mitoxantrone hydrochloride, gemcitabine, etoposide) (CA&U not returned, not participating)
  • Wockhardt UK (vinorelbine ditartrate, oxaliplatin, mitoxantrone hydrochloride) (CA&U not returned, not participating)
  • Zentiva (oxaliplatin) (CA&U not returned, not participating)

Relevant research groups

  • MRC Clinical Trials Unit

Evidence Review Group

  • BMJ Group
  • National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

  • National Collaborating Centre for Cancer

 

 

 

Top


 

Project history

Date Update

26 February 2014

 

Guidance published TA306

 

03 July 2013

The manufacturer of pixantrone (Cell Therapeutics) has requested to submit a patient access scheme.  This scheme has been approved by the Department of Health and in recognition of the exceptional circumstances, the appeal stage of this appraisal topic is suspended.  The FAD and evaluation report will be removed from the NICE website and appeals and factual errors will not be accepted.

NICE has agreed that the appraisal Committee will consider the new evidence on the cost effectiveness of pixantrone at its meeting on 11 September 2013.

17 May 2012 Following an update from the manufacturer related to the UK pricing strategy, this appraisal has had to be rescheduled.  The Committee meeting currently scheduled for 9 August and 11 October have been cancelled and will now take place on 11 September 2013.
10 October 2011 Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations.  Therefore, we now anticipate that the appraisal will begin during late December 2011 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early March 2012.
Top


 

Key documents

This page was last updated: 25 February 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.